FTC: Shkreli may have violated lifetime pharma ban, should be held in contempt
Ars Technica » Scientific Method 2023-01-20
Summary:
Shkreli's latest company, Druglike, may run afoul of his lifetime pharma ban.
Link:
https://arstechnica.com/?p=1911591From feeds:
Berkeley Law Library -- Reference & Research Services » Ars Technica » Scientific MethodCyberlaw » Ars Technica
Music and Digital Media » Ars Technica